Discussion Board

Most Discussed: META AAPL PANW STNE LUMN SLB TSLA TPL ASX:GTG ASML

Topic	Replies	Activity
stock is very weak ,may retest last march lows of 45 Investment Ideas NSE:INTLCONV	0	Apr 22, 2024
Thanks for the article, Bernard! Article Comments TJX Companies: Own This Value Pick	1	Apr 22, 2024
The Nasdaq has had its worst week since 2022. But what now? Investment Ideas	0	Apr 22, 2024
Last week's oil news summed up General Discussions	0	Apr 21, 2024
Thoughts on ANCUF's value at it's current price? Investment Ideas ANCUF	1	Apr 19, 2024
[email protected] General Discussions Financial Calendars	0	Apr 18, 2024
The results show that upadacitinib (RINVOQ®; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission Article Comments Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis	0	Apr 18, 2024
what is the fair price? Article Comments AMD's Cost-Effective Strategy Is Intelligent, but the Valuation Is Troubling	1	Apr 18, 2024
Thanks for sharing your thoughts and insightful analysis.I've noticed that you were referring to Organon stock in the table of drug sales author's est Article Comments Biogen Is Suffering From Doubts About the Future	4	Apr 16, 2024
Great article FUN thank you!. Any guesses on what we might see from the gold and silver miners in the next couple weeks? What's your % of cash at? Article Comments Pan American Silver: Waiting for the Escobal Reopening	3	Apr 16, 2024
Good article! I see it is your first on GuruFocus; thank you for sharing your insights on here! Article Comments American Airlines: Fundamentally a Riskier Bet	0	Apr 16, 2024
Hi Fun, Thank you for another insightful article. PAAS is my third largest position. I was surprised and delighted when it reached 19 and beyond. Just Article Comments Pan American Silver: Waiting for the Escobal Reopening	2	Apr 16, 2024
FUN. Does GuruFocs limit the ability to expand the exhibits? Article Comments Pan American Silver: Waiting for the Escobal Reopening	1	Apr 16, 2024
A great growth company. Organic growth > 10%. With acquisition, growth > 18%. Consistent growth, reasonable valuation. Investment Ideas BRO	1	Apr 15, 2024
This company has a 5 star predictability rank - however the earnings are anything but predictable. This holds no place in Buffett Munger screener :) Investment Ideas AGRO	1	Apr 15, 2024
In today's dynamic market environment, as Overstock boldly ventures into blockchain technology, it's clear that the crypto landscape is rapidly evolvi Article Comments Overstock Has a Bitcoin Problem	0	Apr 15, 2024
https://www.morningstar.com/funds/american-funds-american-balanced-remains-solid-holding General Discussions AMERICAN BALANCED FUND	0	Apr 15, 2024
PHI Group's partnership with CYFS Group to spearhead CO2-1-0 (CARBON) marks a pivotal step towards disruptive carbon mitigation efforts. Leveraging bl Article Comments PHI Group Engages in Blockchain and Crypto Technologies in a New Disruptive Carbon Mitigation Initiative through Environmentally Sustainable projects, CO2-1-0 (CARBON)	0	Apr 15, 2024
RocketFuel's introduction of its Payouts product marks a significant leap forward in streamlining payment processes for businesses. By offering optio Article Comments RocketFuel Launches Its Most Anticipated Crypto Payouts Product	2	Apr 15, 2024
In light of the burgeoning influence of AI in reshaping industries, businesses seek expertise to navigate the complexities of this transformative tech Article Comments Market Caution Prevails Amid Rising Middle East Tensions	0	Apr 15, 2024

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Discussion Board

stock is very weak ,may retest last march lows of 45

Thanks for the article, Bernard!

The Nasdaq has had its worst week since 2022. But what now?

Last week's oil news summed up

Thoughts on ANCUF's value at it's current price?

[email protected]

The results show that upadacitinib (RINVOQ&reg;; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission

what is the fair price?

Thanks for sharing your thoughts and insightful analysis.I've noticed that you were referring to Organon stock in the table of drug sales author's est

Great article FUN thank you!. Any guesses on what we might see from the gold and silver miners in the next couple weeks? What's your % of cash at?

Good article! I see it is your first on GuruFocus; thank you for sharing your insights on here!

Hi Fun, Thank you for another insightful article. PAAS is my third largest position. I was surprised and delighted when it reached 19 and beyond. Just

FUN. Does GuruFocs limit the ability to expand the exhibits?

A great growth company. Organic growth &gt; 10%. With acquisition, growth &gt; 18%. Consistent growth, reasonable valuation.

This company has a 5 star predictability rank - however the earnings are anything but predictable. This holds no place in Buffett Munger screener :)

In today's dynamic market environment, as Overstock boldly ventures into blockchain technology, it's clear that the crypto landscape is rapidly evolvi

https://www.morningstar.com/funds/american-funds-american-balanced-remains-solid-holding

PHI Group's partnership with CYFS Group to spearhead CO2-1-0 (CARBON) marks a pivotal step towards disruptive carbon mitigation efforts. Leveraging bl

RocketFuel's introduction of its Payouts product marks a significant leap forward in streamlining payment processes for businesses. By offering optio

In light of the burgeoning influence of AI in reshaping industries, businesses seek expertise to navigate the complexities of this transformative tech

The results show that upadacitinib (RINVOQ®; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission

A great growth company. Organic growth > 10%. With acquisition, growth > 18%. Consistent growth, reasonable valuation.